"Portal Pressure" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The venous pressure measured in the PORTAL VEIN.
| Descriptor ID |
D017082
|
| MeSH Number(s) |
G09.330.380.076.732.650
|
| Concept/Terms |
Portal Pressure- Portal Pressure
- Pressure, Portal
- Portal Venous Pressure
- Pressure, Portal Venous
- Venous Pressure, Portal
|
Below are MeSH descriptors whose meaning is more general than "Portal Pressure".
Below are MeSH descriptors whose meaning is more specific than "Portal Pressure".
This graph shows the total number of publications written about "Portal Pressure" by people in this website by year, and whether "Portal Pressure" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2008 | 1 | 0 | 1 |
| 2009 | 0 | 1 | 1 |
| 2016 | 0 | 1 | 1 |
| 2018 | 0 | 2 | 2 |
| 2019 | 0 | 1 | 1 |
| 2021 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Portal Pressure" by people in Profiles.
-
The relationship between portal hypertension and portal hypertensive gastropathy. Scand J Gastroenterol. 2022 Mar; 57(3):340-344.
-
A Machine Learning Approach to Liver Histological Evaluation Predicts Clinically Significant Portal Hypertension in NASH Cirrhosis. Hepatology. 2021 12; 74(6):3146-3160.
-
Prioritization of Therapeutic Targets and Trial Design in Cirrhotic Portal Hypertension. Hepatology. 2019 03; 69(3):1287-1299.
-
Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis. Gastroenterology. 2018 10; 155(4):1140-1153.
-
Predictors of clinical outcomes in cirrhosis patients. Curr Opin Gastroenterol. 2018 07; 34(4):266-271.
-
Simtuzumab treatment of advanced liver fibrosis in HIV and HCV-infected adults: results of a 6-month open-label safety trial. Liver Int. 2016 12; 36(12):1783-1792.
-
Endothelin antagonism in portal hypertensive mice: implications for endothelin receptor-specific signaling in liver disease. Am J Physiol Gastrointest Liver Physiol. 2009 Jul; 297(1):G27-33.
-
Effect of the nitric oxide donor V-PYRRO/NO on portal pressure and sinusoidal dynamics in normal and cirrhotic mice. Am J Physiol Gastrointest Liver Physiol. 2008 Jun; 294(6):G1311-7.